Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA reports news on its AI-driven precision medicine software business and the adoption of the SOPHiA DDM Platform by hospitals, laboratories, and biopharma institutions. Company updates commonly cover financial results, analysis volumes, customer additions, U.S. market expansion, and applications that analyze genomic and multimodal data for cancer and rare disorders.
Recurring developments include health-system collaborations, next-generation sequencing workflows for blood cancers and solid tumors, Liquid Biopsy and Enhanced Exomes applications, and management commentary on platform demand, gross margin, operating leverage, and biopharma activity.
SOPHiA GENETICS (NASDAQ:SOPH) partnered with Synnovis to deliver MSK-ACCESS® liquid biopsy testing, powered by SOPHiA DDM™, to lung and breast cancer patients across the U.K. within NHS England’s blood test-first program.
The ctDNA-based test supports about 400 patients per month and is expected to reach 7,000 patients annually, potentially covering roughly one third of all ctDNA tests in England and enabling targeted therapies up to two weeks earlier.
SOPHiA GENETICS (Nasdaq: SOPH) reported Q1 2026 results for the quarter ended March 31, 2026. Revenue was $21.7 million (+22% YoY). IFRS net loss was $19.3 million (up 11% YoY); adjusted EBITDA loss improved to $9.2 million. Adjusted gross margin was 75.4%.
The company performed a record 108,000 SOPHiA DDMTM analyses, increased net dollar retention to 117%, and reaffirmed FY 2026 revenue guidance of $92–$94 million with adjusted EBITDA loss guidance of $29–$32 million.
SOPHiA GENETICS (Nasdaq: SOPH) will release first quarter 2026 financial results before U.S. markets open on Tuesday, May 5, 2026. A conference call to discuss results and business outlook begins at 8:00 a.m. EDT / 2:00 p.m. CET and will be webcast live.
A replay of the webcast will be available on the company's investor relations website after the call.
SOPHiA GENETICS (NASDAQ: SOPH) announced a collaboration with the Mount Sinai Health System to adopt the AI-powered SOPHiA DDM™ Platform for blood cancers and solid tumors to strengthen NGS testing and genomic interpretation.
Mount Sinai will use the platform to reduce manual analysis time, improve turnaround, and scale interpretation across complex genomic datasets; Mount Sinai treats over 4,000 oncology patients annually. The announcement was made at AACR 2026.
SOPHiA GENETICS (Nasdaq: SOPH) reported Q4 2025 revenue of $21.7M (+22% YoY) and full-year 2025 revenue of $77.3M (+19% YoY). Adjusted gross margin expanded to 74.2% in 2025. IFRS net loss was $79.0M for 2025; adjusted EBITDA loss was $41.5M. The company reaffirmed 2026 guidance of $92M–$94M revenue and adjusted EBITDA loss of $29M–$32M, and expects adjusted EBITDA breakeven around end-2026 and positive adjusted EBITDA in H2 2027.
SOPHiA GENETICS (Nasdaq:SOPH) announced leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston.
Jurgi Camblong, CEO and co-founder, and Ross Muken, President, will participate in a fireside chat on March 4, 2026 at 10:30 am EST / 4:30 pm CET. According to the company, a live audio webcast will be available and a replay will be accessible for 90 days after the event.
SOPHiA GENETICS (Nasdaq: SOPH) will release fourth-quarter and full-year 2025 financial results before U.S. markets open on March 3, 2026. A conference call to discuss results and business outlook will begin at 8:00 AM EDT / 2:00 PM CET and will be webcast on the company investor relations website. A replay will be available after the call.
SOPHiA GENETICS (NASDAQ: SOPH) announced the addition of two major U.S. integrated health systems to its network, expanding use of the AI-native, cloud-based SOPHiA DDM™ across West Coast and Midwest laboratories.
The institutions will initially launch genomic testing for up to 60,000 patients annually, use Enhanced Exome for analysis of over 20,000 genes, and together serve a combined population of nearly one million cancer and rare disorder patients.
Summary not available.
Axalta (NYSE:AXTA) announced it won six Business Intelligence Group (BIG) Innovation Awards for product innovations across Refinish, Mobility Coatings, and Industrial Coatings on January 15, 2026. Honored products include a waterborne clearcoat that reduces solvent emissions by >65%, a low-bake OEM coatings system modeled to cut plant energy use by up to 40% and save up to $40M annually in maintenance for a 100,000-vehicle plant, and a clearcoat curing at 80°C that may lower CO2 per vehicle by ~16 kg (~20%). Other winners address EV battery fire resistance, 100% solids UV cabinet coating with zero VOCs, and electrical steel coating for high-speed motor bonding.